New Immunoassay Technology Improves Workflow

Article

Gyros Protein Technologies’ new immunoassay technology includes expanded software to optimize time to results and sample capacity while simplifying workflows.

Gyros Protein Technologies, a provider of automated nanoliter-scale immunoassay platforms and peptide synthesizers and reagents, introduced a new five-compact-disc (CD) model, Gyrolab xPand, on March 19, 2018. The product combines immunoassay technology with expanded software and provides higher throughput, greater flexibility, and faster analysis of large sample numbers, according to the company.

The company reports that its technology significantly accelerates the discovery and development process for new and safer biotherapeutics. Gyrolab xPand updates the Gyrolab platform with more advanced instrumentation and software designed for 21 CFR part 11 compliance.

During assay runs, the new multi-CD platform maintains samples at 2–8 °C. This diminishes the possible adverse effects of on-board sample storage. The product is an open platform with built-in flexibility and can be adapted to the specific needs of each user. For example, different assays can be mixed within a five-CD run while maintaining high quality results. The new software is expected to allow scientists to increase productivity for desktop experiment planning and experiment mapping as well as provide advanced functions for dilution linearity and spike recovery studies for assay qualification.

“The majority of the world’s leading biopharmaceutical companies and CROs [contract research organizations] use Gyrolab technology in discovery, preclinical and clinical development, and bioprocess. They regard the system as a ‘must-have’ to accelerate assay development, sample analysis, and production. Therefore, it is essential that our instrument portfolio expands to address additional requirements from our customers. Gyrolab xPand combines the best features of the Gyrolab platform with the addition of cooling, and many new software capabilities to increase productivity and performance that our customers demand,” said Dan Calvo, CEO and president, Gyros Protein Technologies, in a company press release.

The company will display the unit at the 12th WRIB conference in Philadelphia, PA, on April 9–13, 2018.

Source: Gyros Protein Technologies

Recent Videos
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Related Content
© 2024 MJH Life Sciences

All rights reserved.